Therapy development updates
There are many ongoing clinical and laboratory studies around the world, exploring innovative approaches to treating inherited sight loss.
Search
Search results
Sepul Bio begins clinical trial of ultevursen for USH2A-associated RP
Sepul Bio begins clinical trial of ultevursen for USH2A-associated RP
Tyne & Wear Local Peer Support Group
Saturday 22 August 2026, 1.00pm - 7.00pm - In-person - Come and join Colin and the group at the Tyneside Irish Centre for their latest in-person event in Newcastle.
E-Newsletter September 2026
Our monthly e-Newsletter featuring the latest updates from Retina UK.
Trusts and Foundations
Inherited retinal dystrophies (IRDs) are the leading cause of blindness in working-age people in the UK, and children as young as eighteen-months are regularly diagnosed.
Our Partners
We are proud to work collaboratively with a number of corporate partners to enable our community to live fulfilled lives today as well as supporting the pharmaceutical industry in their mission to develop potential new treatments.
ProQR makes progress with potential treatment for LCA
Despite the challenges of the pandemic, researchers and pharmaceutical companies are still making progress towards delivering new treatments for inherited sight loss.
Exciting developments for new treatment research
In recent years there has, understandably, been a lot of excitement around cutting-edge therapies that target the specific genetic faults underlying inherited sight loss.
Your donations make progress possible
Your generous support allows Retina UK to fund the work of leading scientists who are increasing understanding of inherited sight loss and moving us closer to treatments.
e-Newsletter May 2025
Our monthly e-Newsletter featuring the latest updates from Retina UK.